Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM30FNL)

Drug Name
1-(9-Oxo-9H-fluoren-4-yl)-3-pyridin-2-yl-urea Drug Info
Synonyms
Diarylurea deriv. 15; AC1NS9HQ; BDBM6655; CHEMBL140589; SCHEMBL12856374; ZINC13471114; 1-(9-oxofluoren-4-yl)-3-pyridin-2-ylurea; 3-(9-oxo-9H-fluoren-4-yl)-1-pyridin-2-ylurea; 1-(9-Oxo-9H-fluorene-4-yl)-3-(2-pyridyl)urea; N-(9-Oxo-9H-fluoren-4-yl)-N -pyridin-2-ylurea
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5330596
TTD Drug ID
DM30FNL

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cyclin-dependent kinase 4 (CDK4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Apremilast DMTWS9E Psoriasis vulgaris EA90 Approved [2]
LY2835219 DM93VBZ Breast cancer 2C60-2C65 Approved [3]
Palbociclib DMD7L94 Breast cancer 2C60-2C65 Approved [4]
Ribociclib Succinate DM9CIUW Breast cancer 2C60-2C65 Approved [5]
Trilaciclib DMP5A4T Small-cell lung cancer 2C25.Y Approved [6]
LEE011 DMMX75K Breast cancer 2C60-2C65 Phase 3 [7]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [9]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [10]
G1T38 DMQO2IT Breast cancer 2C60-2C65 Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 4 (CDK4) TT0PG8F CDK4_HUMAN Inhibitor [1]

References

1 Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design. J Med Chem. 2001 Dec 20;44(26):4615-27.
2 Agreement signed with Prostagenics to develop prostate cancer treatment. Innovate Oncology, Inc. 2005.
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2017
5 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
7 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma. Clin Cancer Res. 2013 Nov 15;19(22):6173-82.
8 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
9 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
10 Liposarcoma: molecular genetics and therapeutics. Sarcoma. 2011;2011:483154.
11 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)